Physician profile
Anuj Lal
NPI 1437328895
$19,635.29
in general payments reported to CMS, 2019-2025
70 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $2,275 · 2021: $2,904 · 2022: $2,788 · 2023: $2,999 · 2024: $3,257 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,948 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,947.52 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,048.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $2,181.08 | 2019-2025 | |
| Abbvie INC. | $2,087.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,007.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,445.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,221.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $733.82 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $636.19 | 2020-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.42 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $489.50 | 2020-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.63 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $318.82 | 2019-2023 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $303.72 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $235.61 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $234.92 | 2019-2025 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.